目的:观察DCF 方案治疗局部进展期或转移性胃癌的疗效和不良反应.方法:自2007年10月至2009年8月,42例晚期胃癌患者采用DCF,DXT (多西紫杉醇)75mg/m2,静脉滴注,第1天;DDP(顺铂) 25 mg/m2,第1-3天;CF(亚叶酸钙)200mg/d,静脉滴注2小时,第1-5天;5-FU(氟尿嘧啶) 500mg/m2,第1-5天,静脉滴注5-6小时,3周为1周期,方案治疗,按WHO标准评价近期疗效和不良反应,随访疾病进展时间(TTP)和中位生存期(MST).结果:全组42例均可评价疗效,其中CR 3例,PR 19例,SD 11例,PD 9例.有效率(RR)为54.7%,中位TTP为5.5个月,中位MST为10个月.不良反应主要是骨髓抑制及胃肠道反应,其次为口腔黏膜炎、腹泻及周围神经毒性.结论:DCF方案治疗晚期胃癌的疗效较好,不良反应可以耐受.%Objective:To evaluate the efficacy and adverse effects of docetaxel combined with cisplatin and fluorouracil in treating patients with advanced gastric cancer. Methods: From October 2007 to August 2009, 42 cases of advanced gastric cancer patients were treated with docetaxel combined with cisplatin and fluorouracil. The efficay and adverse effects were evaluated according WHO standard. TTP and MST were observed at the same time. Results: All 42 cases were evaluable. Among them, 3 achieved complete response( CR ), 19 partial response( PR ), 11 stable response( SD ), 9 progression disease( PD ). Overall reaponse( CR + PR ) rate was 54.7％, TTP was 5.5 months and MST was 10 months. Major toxicity was myelosuppression, followed by enteric reaction, dental ulcer, diarrhea and perineural toxicity. Conclusion: Docetaxel combined with cisplatin and fluorouracil is effective and its toxicity is tolerable in treating advanced gastric cancer.
展开▼
